Boston Scientific Corporation
BSX
$100.02
$0.970.98%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.27% | 18.25% | 19.08% | 20.68% | 44.75% |
| Total Depreciation and Amortization | 1.79% | 3.38% | -6.61% | 13.73% | -1.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 352.50% | -136.36% | 0.92% | 257.38% | -84.24% |
| Change in Net Operating Assets | -81.12% | 134.37% | -309.26% | 95.18% | 179.43% |
| Cash from Operations | 4.43% | 137.71% | -62.84% | 45.31% | 23.25% |
| Capital Expenditure | -15.29% | 16.04% | 32.49% | -54.75% | -15.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 74.63% | -322.18% | 93.01% | -203.28% | -2,247.92% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -262.50% | 154.05% | -572.73% | 90.91% | -77.94% |
| Cash from Investing | 55.42% | -125.20% | 86.50% | -159.57% | -426.57% |
| Total Debt Issued | -- | -100.00% | 724.34% | -- | -- |
| Total Debt Repaid | 31.53% | 76.05% | -- | -- | -- |
| Issuance of Common Stock | 259.38% | -72.17% | 310.71% | -70.83% | 269.23% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 93.10% | 55.04% | -4,200.00% | 96.63% | -4,350.00% |
| Cash from Financing | 69.41% | -245.92% | 8.88% | 2,957.14% | -70.83% |
| Foreign Exchange rate Adjustments | -200.00% | -94.87% | 533.33% | -250.00% | 700.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | 0.00% | -200.00% |
| Net Change in Cash | 512.92% | -156.87% | 115.31% | -394.92% | -172.97% |